Nine drugmakers including Gilead, Merck, Amgen, Bristol Myers Squibb, GSK, Novartis, Sanofi, Genentech, and Boehringer Ingelheim recently signed voluntary most-favored-nation (MFN) pricing deals with the White House to align US prices with lower international rates123.
Regeneron, along with Johnson & Johnson and AbbVie, are the three remaining companies from an initial group of 17 that have not yet agreed, though analysts expect them to join soon12.
The deals provide MFN prices to Medicaid programs, enable direct-to-consumer sales via TrumpRx.gov launching in 2026, and include commitments for new drugs, with enforcement details unclear123.
Announced in December 2025 following a May 2025 Executive Order and July 2025 letters to drugmakers, these agreements aim to end foreign 'free riding' on US innovation35.
Sources:
1. https://www.healthcaredive.com/news/trump-most-favored-nation-drug-price-deals/808504/
2. https://www.pharmacytimes.com/view/trump-announces-pricing-deals-with-9-drugmakers-expanding-most-favored-nation-drug-pricing-strategy
3. https://www.whitehouse.gov/fact-sheets/2025/12/fact-sheet-president-donald-j-trump-announces-largest-developments-to-date-in-bringing-most-favored-nation-pricing-to-american-patients/
5. https://www.whitehouse.gov/fact-sheets/2025/07/fact-sheet-president-donald-j-trump-announces-actions-to-get-americans-the-best-prices-in-the-world-for-prescription-drugs/